Epidemiology and optimal management of polymyalgia rheumatica

Drugs and Aging

Volumn 13, Issue 2, 1998, Pages 109-118

  Labbe, Pierre ^a   Hardouin, Pierre ^a  

^a Institut Calot Helio Marin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; DAPSONE; GOLD SALT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TENIDAP;

ADULT; AGED; ARTICLE; CAUCASIAN; GIANT CELL ARTERITIS; HUMAN; IMMUNOGENETICS; MAJOR CLINICAL STUDY; MYOPATHY; ORAL DRUG ADMINISTRATION; PREVALENCE; PRIORITY JOURNAL; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SEX DIFFERENCE;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; POLYMYALGIA RHEUMATICA; SEX FACTORS; TEMPORAL ARTERITIS;

EID: 0031686729     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199813020-00003     Document Type: Article

References (73)

1. Bird HA, Esselinckx W, Dixon AS, et al. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 1974; 38: 434-9
2. Jones JG, Hazleman BL. Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis 1981; 40: 1-5
3. Salvarani C, Macchioni P, Zizzi F, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum 1991; 34: 351-6
4. Weyand CM, Hunder NNH, Hicok KC, et al. HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis. Arthritis Rheum 1994; 37: 514-20
5. Haworth S, Ridgeway J, Stewart I, et al. Polymyalgia rheumatica is associated with both HLA-DRBI*0401 and DRB1*0404. Br J Rheumatol 1996; 35: 632-5
6. Hamrin B. Polymyalgia arteritica. Acta Med Scand Suppl 1972; 533: 1-131
7. Fauchald P, Rygvold O, Oystese B. Temporal arteritis and polymyalgia rheumatica: clinical and biopsy findings. Ann Intern Med 1972; 77: 845-52
8. Harlé JR, Disdier P, Bolla G, et al. Relations entre pseudopolyarthrite rhizomélique et myopathie mitochondriale: 24 observations. Presse Med 1994; 23: 15-8
9. Smith CA, Fidler WJ, Pinals RS. The epidemiology of giant cell arteritis: report of a ten years study in Shelby county. Tennessee. Arthritis Rheum 1983; 25: 1214-8
10. Noltrop S, Svensson B. High incidence of polymyalgia rheumatica and giant cell arteritis in a Swedish community. Clin Exp Rheumatol 1991; 9: 351-5
11. Boesen P, Sörensen SF. Giant cell arteritis, temporal arteritis and polymyalgia rheumatica in a Danish county: a prospective investigation 1982-85. Arthritis Rheum 1987; 30: 294-9
12. Chuang TY, Hunder GG, Ilstrup DM, et al. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982; 97: 672-80
13. Salvarani C, Gabriel SE, O'Fallon WM, et al. Epidemiology of polymyalgia rheumatica in Olmsted county, Minnesota, 1970-1991. Arthritis Rheum 1995; 38: 369-73
14. Dailey MP, McCarty DJ. Polymyalgia rheumatica begins at 40. Arch Intern Med 1979; 139: 743-4
15. Cimmino MA, Caporali R, Montecucco CM, et al. A seasonal pattern in the onset of polymyalgia rheumatica. Ann Rheum Dis 1990; 49: 521-3
16. O'Brien JP, Regan W. Are we losing focus on the internal elastic lamina in giant cell arteritis? Arthritis Rheum 1992; 35: 794-8
17. Calamia KT, Moore SB, Elveback LR, et al. HLA-DR locus antigens in polymyalgia rheumatica and giant cell arteritis. J Rheumatol 1981; 8: 993-6
18. Armstrong RD, Behn A, Myles A, et al. Histocompalibility antigens in polymyalgia rheumatica and giant cell arteritis. J Rheumatol 1983; 10: 659-61
19. Richardson JE, Gladman DD, Fam A, et al. HLA-DR4 in giant cell arteritis: association with polymyalgia syndrome. Arthritis Rheum 1987; 30: 1293-7
20. Schaufelberger C, Bengtsson BA, Andersson R. Epidemiology and mortality in 220 patients with polymyalgia rheumatica. Br J Rheumatol 1995; 34: 261-4
21. Wagner AD, Bjornsson J, Bartley GB, et al. Interferon-gamma-producing T-cells in giant cell arteritis represents a minority of tissue-infiltrating cells and are located distant from the site of pathology. Am J Pathol 1996; 148: 1925-33
22. Weyand CM, Goronzy JJ, Hunder GG. Response to cytokines in polymyalgia rheumatica and giant cell arteritis [letter]. Ann Intern Med 1995; 122: 634
23. Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine pattern in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994; 21: 484-91
24. Bengtsson BA, Malmvall BE. Giant cell arteritis. Acta Med Scand Suppl 1982; 658: 18-28
25. Spiera H, Davison S. Treatment of polymyalgia rheumatica [letter]. Arthritis Rheum 1982; 25: 120
26. Hunder G, Allen GL. The relationship between polymyalgia rheumatica and giant cell arteritis. Geriatrics 1973; 28: 134-42
27. Hunder GG, Allen GL. Giant cell arteritis: a review [letter). Bull Rheum Dis 1978-1979; 29: 980
28. Healey LA, Sheets PK. The relation of polymyalgia rheumatica to rheumatoid arthritis. J Rheumatol 1988; 15: 750-2
29. Mattei JP, Bendahan D, Erkintalo M, et al. P-31 magnetic resonance spectroscopy demonstrates unaltered muscle energy utilization in polymyalgia rheumatica. Arthritis Rheum 1997; 40: 1817-22
30. Lafforgue P, Senbel E, Figarella-Branger D, et al. Systemic amyloidosis AL with temporal artery involvement revealing lymphoplasmacytic malignancy in a man presenting as polymyalgia rheumatica. Ann Rheum Dis 1993; 52: 158-60
31. Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis: II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis 1989; 48: 662-6
32. Cimmino MA, Moggiana G, Montecucco C, et al. Long-term treatment of polymyalgia rheumatica with deflazacort. Ann Rheum Dis 1994; 53: 331-3
33. Krogsgaard MR, Lund B, Johnsson B. A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica. J Rheumatol 1995; 22: 1660-2
34. Krogsgaard MR, Thamsborg G, Lund B. Changes in hone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort. Ann Rheum Dis 1996; 55: 143-6
35. Behn AE, Perera T, Myles B. Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis 1983; 42: 374-8
36. Myles AB, Perera T, Ridley MG. Prevention of blindness in giant cell arteritis by corticosteroid treatment. Br J Rheumatol 1992; 31: 103-5
37. Rosenfield SI, Kosmorsky GS, Klingele TG, et al. Treatment of temporal arteritis with ocular involvement. Am J Med 1986; 80: 143-5
38. Hamilton CR. Giant cell arteritis: including temporal arteritis and polymyalgia rheumatica. Medicine Baltimore 1971; 50: 1-27
39. Hubault A. La pseudopolyarthrite rhizomélique. Presse Med 1983; 12: 157-9
40. Ayoub WT, Franklin CM, Torretti D. Polymyalgia rheumatica: duralion of therapy and long-term outcome. Am J Med 1985; 79: 309-15
41. Bengtsson BA, Malmvall BE. Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica: a follow-up study on ninety patients treated with corticosteroids. Acta Med Scand 1981; 209: 337-45
42. Healey LA. Relation of giant cell arteritis to polymyalgia rheumatica. Baillieres Clin Rheumatol 1991; 5: 371-8
43. Bengtsson BA. Giant cell arteritis. Curr Opin Rheumatol 1990; 2: 60-5
44. Kyle V, Hazleman B. Treatment of polymyalgia rheumatica and gianl cell arteritis: I. Steroid regimens in the first two months. Ann Rheum Dis 1989; 48: 658-61
45. Huston KA, Hunder GG, Lie JT, et al. Temporal arteritis: a 25 year epidemiologic, clinical, and pathological study. Ann Intern Med 1978; 88: 162-7
46. Lundberg I, Hedfors E. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis. J Rheumatol 1990; 17: 1340-5
47. Kyle V, Hazleman BL. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 1993; 52: 847-50
48. Delecoeuillerie G, Joly P, Cohen de Lara A, et al. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 1988; 47: 733-9
49. Kyle V, Hazleman B. Stopping steroids in polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1990; 29: 344-5
50. Gabriel SF, Sunku J, Salvarani C, et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997; 40: 1873-8
51. Tahorn J. Epidural lipomatosis as a cause of spinal cord compression in polymyalgia rheumatica. J Rheumatol 1991; 18: 286-8
52. Dolan AL, Moniz C, Dasgupta B, et al. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Arthritis Rheum 1997; 40: 2022-9
53. David-Chaussé J, Dehaix J, Lehan A. Résultats d'une enquête régionale sur le traitement de la pseudopolyarthrite rhizomélique et de l'artérite temporale. Rev Rhum Mal Osteoartic 1983; 50: 563-76
54. Littman BH, Bjarnason D, Bryant G, et al. Steroid sparing activity of tenidap in patients with polymyalgia rheumatica: a multicenter double blind randomized placebo controlled study. J Rheumatol 1995; 22: 1097-1103
55. Ferraccioli G, Salaffi F, De Vita S, et al. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol 1996; 23: 624-8
56. Krall PL, Mazanec DJ, Wilke WS. Methotrexate for corticosteroid resistant polymyalgia rheumatica and giant cell arteritis. Cleve Clin J Med 1989; 56: 253-7
57. Settas L, Dimitriadis G, Sfetsios T, et al. Methotrexate versus azathioprine in polymyalgia rheumatica - giant cell arteritis: a double blind, crossover trial. Arthritis Rheum 1991; 34 Suppl.: S72
58. Feinberg HL, Sherman JD, Schrepferman CG, et al. The use of methotrexate in polymyalgia rheumatica. J Rheumatol 1996; 23: 1550-2
59. Van der Veen MJ, Dinant HJ, Van Booma-Frankfort C, et al. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumalica and giant cell arteritis? Ann Rheum Dis 1996; 55: 218-23
60. Doury P, Pattin S, Eulry F, et al. Traitement de la maladie de Horton et de la pseudopolyarthrite rhìzomélique par la dapsone: résultats préliminaires [letter]. Presse Med 1983; 12: 104
61. Liozon F, Vidal E, Bonnetblanc JM, et al. La disulone dans le traitement de la maladie de Horion: expérience sur 20 malades. Ann Med Interne 1986; 137: 299-306
62. De Sylva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double blind study. Ann Rheum Dis 1986; 45: 136-8
63. Forestier J, Certonciny A. Pseudopolyarthrite rhizomélique. Rev Rhum Mal Osteoartic 1953; 20: 854-63
64. Galezowski N, Nguyen TD, Blanche P. Sulfamethoxazole/trimethoprim therapy for polymyalgia rheumatica: report of 5 cases. J Rheumatol 1997; 24: 1451-2
65. Cid MC, Monteagudo J, Oristrell J, et al. Von Willebrand factor in the outcome of temporal arteritis. Ann Rheum Dis 1996; 55: 927-30
66. Salvarani C, Boiardi L, Macchioni P, et al. Serum soluble CD4 and CD8 levels in polymyalgia rheumatica. J Rheumatol 1994; 21: 1865-9
67. Salvarani C, Macchioni P, Boiardi L, et al. Soluble interleukin 2 receptors in polymyalgia rheumatica/giant cell arteritis: clinical and laboratory correlations. J Rheumatol 1992; 19: 1100-6
68. Macchioni P, Boiardi L, Meliconi R, et al. Elevated soluble-intercellular adhesion molecule 1 in the serum of patients with polymyalgia rheumatica: influence of steroid treatment. J Rheumatol 1994; 21: 1860-4
69. Helfgott SM, Kieval RI. Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate. Arthritis Rheum 1996; 39: 304-7
70. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid induced osteoporosis. N Engl J Med 1997; 337: 382-7
71. Wilke WS. Large vessel vasculitis. Baillieres Clin Rheumatol 1997; 11: 285-313
72. Robb-Nicholson C, Chang RW, Anderson S, et al. Diagnostic value of the history and examination in giant cell arteritis: a clinical pathological study of 81 temporal artery biopsies. J Rheumatol 1988; 15: 1793-6
73. Gabriel SE, O'Fallon WM, Achkar AA, et al. The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis. J Rheumatol 1995; 22: 93-6